Fulvestrant Patent Expiration

Fulvestrant is a drug owned by Fresenius Kabi Usa Llc. It is protected by 3 US drug patents filed in 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 17, 2034. Details of Fulvestrant's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833459 Fulvestrant formulations
Feb, 2034

(9 years from now)

Active
US10188663 Fulvestrant formulations
Feb, 2034

(9 years from now)

Active
US9271990 Fulvestrant formulations
May, 2034

(9 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Fulvestrant is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fulvestrant's family patents as well as insights into ongoing legal events on those patents.

Fulvestrant's family patents

Fulvestrant has patent protection in a total of 1 countries. It has a significant patent presence in the US with 100.0% of its patents being US patents. Click below to unlock the full patent family tree for Fulvestrant.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Fulvestrant's generic launch date based on the expiry of its last outstanding patent is estimated to be May 17, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Fulvestrant Generics:

Fulvestrant is the generic name for the brand Fulvestrant. 14 different companies have already filed for the generic of Fulvestrant, with Eugia Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Fulvestrant's generic





About Fulvestrant

Fulvestrant is a drug owned by Fresenius Kabi Usa Llc. It is used for treating hormone receptor-positive advanced breast cancer in postmenopausal women. Fulvestrant uses Fulvestrant as an active ingredient. Fulvestrant was launched by Fresenius Kabi Usa in 2019.

Market Authorisation Date:

Fulvestrant was approved by FDA for market use on 20 May, 2019.

Active Ingredient:

Fulvestrant uses Fulvestrant as the active ingredient. Check out other Drugs and Companies using Fulvestrant ingredient

Treatment:

Fulvestrant is used for treating hormone receptor-positive advanced breast cancer in postmenopausal women.

Dosage:

Fulvestrant is available in solution form for intramuscular use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
250MG/5ML (50MG/ML) SOLUTION Prescription INTRAMUSCULAR